Risk Management



Anti-VEGF Drugs for Adults

Vascular endothelial growth factor, or VEGF, is a protein that stimulates the growth of new blood vessels. Ophthalmologists administer intravitreal anti-VEFG agents to adults for a variety of indications. These include Avastin, BEOVU, Lucentis, and Eylea. Sometimes the indication has been approved by the Food and Drug Administration (FDA), other times it is off-label, or the medication itself may never have been approved for any eye indication.

Time out before intravitreal injections is a sample protocol to verify the patient, drug, dose, etc.

AntiVEGF for adults (updated 2023) presents suggestions to increase patient safety and decrease the likelihood of lawsuits related to these drugs. It also provides information about our revised sample consent documents for anti-VEGF agents:

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.

61864684